Sanofi-Aventis Menactra Approved; Launch Awaits ACIP Recommendations
Executive Summary
Sanofi-Aventis' launch of its meningococcal conjugate vaccine Menactra will await formal recommendations for use by the Centers for Disease Control & Prevention's Advisory Committee on Immunization Practices next month
You may also be interested in...
Sanofi’s Adacel Tdap Vaccine Receives Broader Approval Than GSK’s Boostrix
Sanofi-Aventis' postmarketing commitments for Adacel include a 16,000-patient epidemiologic safety surveillance study of the tetanus, diphtheria and acellular pertussis vaccine
Sanofi’s Adacel Tdap Vaccine Receives Broader Approval Than GSK’s Boostrix
Sanofi-Aventis' postmarketing commitments for Adacel include a 16,000-patient epidemiologic safety surveillance study of the tetanus, diphtheria and acellular pertussis vaccine
Menactra Launches For 11, 12, 15 Year Olds; First In Wave Of Teen Vaccines?
Sanofi-Pasteur will have approximately 5 mil. doses of Menactra (meningococcal quadrivalent conjugate vaccine) available for use in the U.S. during the first 12 months following launch